Current coverage3 articles · 3 publishers
FTC: Martin Shkreli repeatedly violated lifetime pharma ban
- Published
- Updated
- Reports
- 3 from 3 publishers
The FTC and seven state attorneys general say Martin Shkreli 'flagrantly and repeatedly' violated his lifetime ban from the pharmaceutical industry, including by trading pharma stocks. The claim stems from his role in an illegal scheme to monopolize the drug Daraprim.
AI summary · Original reporting is linked alongsideHow the outlets frame it
3 outlets, each read from its own headline and opening- Stands outBusiness Insider (mildly sensational).
- PlainestThe Guardian and CNBC.
Tap a logo to see the outlet, the headline it was read from, and where it sits on every measure.
Does the report cast the development as bad news or good news?
Both read as neutral.
1 outlet not placed: the reading was split between distant levels.
Does the report play the story up to grab attention?
Business Insider stands apart as mildly sensational; the other 2 read as measured.
Do the words judge rather than describe?
All 3 read as neutral wording.
Does the report give room to one side only?
Only CNBC could be placed, as straight.
2 outlets not placed: the reading was split between distant levels.
All 3 outlets and the headlines they were read from
Business Insider
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma banFraming: not placed · Sensationalism: Mildly sensational · Loaded language: Neutral wording · Slant: not placed
CNBC
Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claimFraming: Neutral · Sensationalism: Measured · Loaded language: Neutral wording · Slant: Straight
The Guardian
FTC and seven states seek contempt ruling against Shkreli over pharma banFraming: Neutral · Sensationalism: Measured · Loaded language: Neutral wording · Slant: not placed
Each outlet is read blind: a classifier sees its headline and opening next to the story's own headline, without the outlet's name, and scores how the report presents the story. A logo sits at the classifier's average reading, so it can fall between two levels. These readings compare coverage of this story only; they are not ratings of the outlets.
Where the outlets diverge
Two headlines from opposite endsSensationalism · Measured → Sensational
The story as a whole
Read from all the reports togetherAffects a specific US group
Single event
No time pressure
Not disputed in the text
Official statement or press release
Attributed to named officials or documents
Not political
No violence reported
Other signals
9 found · 13 not present- Article typeNews report
- TopicCourts and legal
- Government levelMultiple levels
- Where it happensUnited States national
- What a reader getsNew facts
- ToneNeutral and factual
- Viewpoints presentedOne viewpoint only
- Main political actorA government agency
- Public healthA treatment or drug
- Policy areanot present
- Civil liberties questionnot present
- Market relevancenot present
- Which marketunclear
- Market horizonnot present
- Who is economically affectednot present
- Corporate dimensionnot present
- Conflict dimensionnot present
- Conflict direction reportednot present
- Humanitarian impactnot present
- Public safetynot present
- Scientific evidencenot present
- Legal risk in the reportingnot present
The 10 stories everyone is covering, in your inbox at 7 am your time.
grouped.news is free, independent and has no paywall. If it saves you time, chip in.Buy us a coffee ↗